期刊
DRUG DISCOVERY TODAY
卷 25, 期 9, 页码 1754-1761出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2020.07.010
关键词
-
资金
- Hong Kong Baptist University [FRG2/17-18/003]
- Health and Medical Research Fund [HMRF/14150561]
- National Natural Science Foundation of China (China) [21775131]
- Hong Kong Baptist University Century Club Sponsorship Scheme 2019
- Interdisciplinary Research Matching Scheme [RC-IRMS/16-17/03]
- Interdisciplinary Research Clusters Matching Scheme [RC-IRCs/17-18/03]
- SKLEBA [SKLP_1920_P02]
- HKBU Strategic Development Fund [SKLP_1920_P02]
- Science and Technology Development Fund, Macau SAR [0072/2018/A2]
- University of Macau [MYRG2018-00187-ICMS, MYRG-201900002-ICMS]
- [C5026-16G]
S100 calcium-binding protein B (S100B) is overexpressed in various malignant tumors, where it regulates cancer cell proliferation and metabolism by physical interactions with other molecules. Interfering with S100B-effector protein interactions is a potential strategy to treat malignant tumors. Although some S100B inhibitors have been discovered by virtual screening (VS), most target the S100B-p53 interaction. Hence, there is scope for the discovery of other S100B-effector protein interaction modulators for malignant tumors. In this review, we provide an overview of S100B-effector protein interaction inhibitor discovery using VS and discuss promising S100B-effector protein interaction targets that permit in silico analysis for drug discovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据